Table 1 Relationship between BC040587 expression and clinicopathological features in breast cancer patients
From: Role of BC040587 as a predictor of poor outcome in breast cancer
loc285194 | |||||
|---|---|---|---|---|---|
Characteristics | Low | High | n | X2 | p |
Age(years) | 0.175 | 0.675 | |||
 <50 | 32 (47.8%) | 35 (52.2%) | 67 | ||
 ≥50 | 43 (51.2%) | 41 (48.8%) | 84 | ||
Menopausal status | 4.199 | 0.040 | |||
 Pre | 28 (40.6%) | 41 (59.4%) | 69 | ||
 Post | 47 (57.3%) | 35 (42.7%) | 82 | ||
MT Family Hix | 0.028 | 0.867 | |||
 No | 61 (48.8%) | 64 (51.2%) | 125 | ||
 Yes | 14 (48.3%) | 15 (51.7%) | 29 | ||
Tumor size (cm) | 0.853 | 0.356 | |||
 ≦2 cm | 22 (44%) | 28 (56%) | 50 | ||
 >2 cm | 52 (52%) | 48 (48%) | 100 | ||
Node status | 0.479 | 0.489 | |||
 Negative | 36 (45%) | 44 (55%) | 80 | ||
 Positive | 33 (50.8%) | 32 (49.2%) | 65 | ||
ER status | 0.047 | 0.828 | |||
 Negative | 26 (48.1%) | 28 (51.9%) | 54 | ||
 Positive | 47 (50%) | 47 (50%) | 94 | ||
PR status | 0.016 | 0.900 | |||
 Negative | 28 (50%) | 28 (50%) | 56 | ||
 Positive | 46 (48.9%) | 48 (51.1%) | 94 | ||
HER-2 status | 0.342 | 0.559 | |||
 Negative | 44 (51.8%) | 41 (48.2%) | 85 | ||
 Positive | 31 (47%) | 35 (53%) | 66 | ||
P53 status | 1.525 | 0.217 | |||
 Negative | 25 (44.6%) | 31 (55.4%) | 56 | ||
 Positive | 31 (56.4%) | 24 (43.6%) | 55 | ||
Ki67 status | 0.039 | 0.844 | |||
 Negative | 35 (50.7%) | 34 (49.3%) | 69 | ||
 Positive | 20 (48.8%) | 21 (51.2%) | 41 | ||
Differentiation | 4.468 | 0.035 | |||
 Well | 34 (43%) | 45 (57%) | 79 | ||
 Poor | 35 (61.4%) | 22 (38.6%) | 57 | ||
TNM stage | 0.002 | 0.964 | |||
III | 53 (47.3%) | 59 (52.7%) | 112 | ||
 III | 15 (46.9%) | 17 (53.1%) | 32 | ||